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Background: Intraductal papillary mucinous neoplasms (IPMN) are pr cursors of pancreatic 
cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few 
urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC).  
Here, we seek to assess their ability to detect high-risk IPMN. 
Methods: Urine was collected from patients undergoing pancreatic resection and healthy 
controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel 
Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by 
ELISA and analyzed by Kruskal-Wallis. 
Results: Median urinary TIMP-1 levels were significantly lower in healthy controls 
(n=9;0.32ng/mg creatinine) compared to PDAC (n=13;1.95) but not significantly different 
between low/moderate-grade (n=20;0.71) and high-grade/invasive IPMN (n=20;1.12). No 
significant difference in urinary LYVE-1 was detectd between IPMN low/moderate 
(n=16;0.37ng/mg creatinine) and high/invasive grades (n=21;0.09). Urinary PGEM levels were 
not significantly different between groups.  






Pancreatic cancer remains one of deadliest cancers in the United States.  By 2030, it is 
predicted to become the second leading cause of cancer-related death (1).  In 2019 alone, 
approximately 56,770 people will be newly diagnosed with pancreatic cancer and of these, about 
45,750 will succumb to their disease (2).  These sobering statistics are in part due to the typical 
late-stage diagnosis and the lack of curative surgical or treatment options for the majority of 
pancreatic cancer patients.  Recognizing these challenges and the need to intervene earlier in 
order to improve patient outcome, recent research efforts have turned towards the early detection 
and/or prevention of pancreatic cancer.   
A type of mucinous pancreatic cystic lesion known as intraductal papillary mucinous 
neoplasm (IPMN) is an established precursor that can develop into pancreatic cancer (3).  Early 
differential diagnosis and appropriate management of these precursors, many of which are 
incidentally detected on cross-sectional imaging, may provide a much-needed clinical window of 
opportunity.  In fact, the number of IPMN now account for up to 50% of all resected pancreatic 
cysts (4).  Pre-malignant IPMN are thought to progress step-wise through increasing grades of 
dysplasia, from low/moderate grade to high grade, towards invasive cancer.  While 
low/moderate-grade IPMN can be safely monitored as low-risk, high-grade and invasive IPMN 
are high-risk for malignant transformation and should be resected in fit patients.  Although the 
International Consensus Guidelines, which are based upon clinical and radiological features, aid 
in the complex clinical management of IPMN, accurate pre-operative risk stratification is still 
difficult to achieve resulting in patient over- and under-treatment (5).    
Biomarker discovery is an important part of efforts to improve the screening, diagnosis, 
and risk stratification of pancreatic cysts.  Promising biomarkers that correlate with IPMN 
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dysplasia have been identified in blood and pancreati  cyst fluid, but to date none has been 
reported in urine (6, 7).  However, a few urinary biomarkers have been shown to be predictive of 
pancreatic ductal adenocarcinoma (PDAC) or pancreati  c ncer risk (8-10).  These include 
TIMP-1 (Tissue Inhibitor of Metalloproteinase-1), LYVE-1 (Lymphatic Vessel Endothelial 
Receptor 1), and PGEM (Prostaglandin E Metabolite).  TIMP-1 is involved in regulating 
degradation of the extracellular matrix, and LYVE-1 is a lymphatic receptor for hyaluronan, a 
major component of the extracellular matrix.  PGEM is the stable metabolite of the inflammatory 
mediator prostaglandin E2 (PGE2).  In the present study, we seek to validate these prior findings 
and determine whether these candidate urinary biomarkers are similarly predictive of high-risk 
IPMN.    
METHODS 
Patients, Sample Collection 
After obtaining informed consent, urine samples were collected at the time of pancreatic 
resection (pre-surgery).  All patients underwent surgical resection with confirmed pathological 
diagnosis (chronic pancreatitis, pancreatic cyst, or PDAC).  IPMN dysplastic grade was 
determined according to the World Health Organization criteria.  Urine samples were also 
obtained from healthy volunteers.  Samples were placed on ice, centrifuged (4oC, 3000 rpm, 15 
minutes), and aliquoted.  Aliquots were stored at -80°C and subsequently thawed on ice for 
biomarker testing.  Patient demographics were obtained through electronic medical record 
review.  All patient and experimental data were gathered and stored in compliance with the 




 For the three biomarkers, PDAC and IPMN study patients were selected for testing 
based upon bank inventory to avoid depleting samples from any one patient.  In some 
cases, the same patient was assayed for all three markers but in others, different patients 
were tested.  The same healthy controls were tested for TIMP-1 and LYVE-1.  Samples 
collected from patients with chronic pancreatitis, pseudocyst, SCN, MCN were only tested 
for one biomarker, either LYVE-1 or PGEM.   
Urinary PGEM levels were measured using a commercially available ELISA (Cayman 
Chemical Company, Ann Arbor, MI) according to the manufacturer’s protocol.  Similarly, levels 
of TIMP-1 (R&D Systems, Minneapolis, MN) and LYVE-1 (RayBiotech, Inc., Norcross, GA) 
were determined by ELISA.  Absolute concentrations determined by ELISA were normalized to 
urinary creatinine (Cayman Chemical Company, Ann Arbor, MI). 
Statistics 
Baseline demographic data were compared between groups by ANOVA for continuous 
data and chi-square for categorical data.  Data were also adjusted for age and analyzed by 
ANCOVA.  Means and/or medians were determined using GraphPad Prism (version 8).  
Biomarker concentrations were analyzed by the Kruskal-Wallis test and if p<0.05, followed by 
post-test analysis.  P-values of <0.05 were considered statistically significant.  
RESULTS 
Three independent pilot studies with different but overlapping patient groups were 
performed to evaluate the candidate biomarkers.  Urinary TIMP-1 levels were determined in a 
total of 62 individuals, including 9 healthy controls.  Of the 53 patients all of whom underwent 
pancreatic resection, 20 were pathologically confirmed as low/moderate-grade IPMN, 20 as 
high-grade/invasive IPMN, and 13 as PDAC.  Healthy controls were significantly younger than 
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the three patient groups (mean age 38.7 years vs. 67.1 [low/moderate], 64.9 [high/invasive], 67.7 
[PDAC]; p<0.0001); gender was not significantly different between the 4 groups (22, 45, 55, 
38% males respectively; p=0.41).  Urinary TIMP-1 levels (median [interquartile range]) were 
significantly lower in the healthy control group (0.32 [0.30-1.18] ng/mg creatinine) compared to 
PDAC (1.95 [0.95-4.15]; p=0.016) by Kruskal-Wallis and post-hoc tests (Figure 1A).  However, 
TIMP-1 levels were not significantly different between any other groups, including IPMN 
low/moderate (0.71 [0.51-3.73] versus high/invasive grades (1.12 [0.86-1.72] ng/mg creatinine; 
p>0.999).  Similar results were obtained after adjusting for age.  
Urinary LYVE-1 levels were evaluated in 9 healthy controls and 78 patients with 
confirmed pathologic diagnosis of chronic pancreatitis (n=14), low/moderate-grade IPMN 
(n=16), high-grade/invasive IPMN (n=21) and PDAC (n=27).  The healthy control and chronic 
pancreatitis groups were each significantly younger in age than the other three patients groups 
(mean ages 38.7 and 53.8 years vs. 64.6 [low/moderate], 64.1 [high/invasive], 67.9 [PDAC]; 
p<0.0001); there was no significant difference in ge der between the 5 groups (22, 50, 56, 67, 
41% males respectively; p=0.18).  Urinary LYVE-1 levels (median [interquartile range]) were 
found to be significantly lower in healthy controls (0.03 [0.02-0.05] ng/mg creatinine) when 
compared to patients with PDAC (0.32 [0.15-0.68]; p=0.0006) or chronic pancreatitis (0.17 
[0.05-1.70]; p=0.012) or IPMN low/moderate-grade (0.37 [0.19-0.73; p=0.001) by Kruskal-
Wallis followed by post-hoc analysis (Figure 1B).  In contrast, no significant difference in 
LYVE-1 concentration was detected between IPMN low/moderate and high/invasive grades 




The third urinary biomarker candidate, PGEM, was evaluated in 96 patients. Pancreatic 
cysts representing various stages of malignant progression were tested, including benign 
pseudocysts (n=10) and serous cystic neoplasms (SCN; n=13), pre-malignant lesions such as 
mucinous cystic neoplasm (MCN; n=14) and low/moderate-grade IPMN (n=19), and lesions at 
high-risk for malignancy such as high-grade/invasive IPMN (n=20) and PDAC (n=20).  Mean 
age but not gender differed significantly between the groups (p=0.0002 and 0.51 respectively). 
Normalized urinary PGEM levels (median [interquartile range], ng/mg creatinine) were not 
significantly different between any of the groups te ted (pseudocyst: 0.30 [0.18-1.05 ]; SCN: 
0.45 [0.26-1.07]; MCN: 0.27 [0.11-0.58]; low/moderate IPMN: 0.25 [0.11-0.85]; high/invasive 
IPMN: 0.64 [0.29-0.83]; PDAC: 0.43 [0.26-1.39] (p=0.24, Kruskal-Wallis) (Figure 2). Similar 
results were obtained after adjusting for age.   
DISCUSSION 
Biomarkers of disease may be protein-, DNA-, or metabolite-based and found in 
biological material such as biofluids (i.e. blood, urine, bile), stool, or tissue.  A urinary biomarker 
is especially attractive because urine can be collected in a non-invasive manner.  Recent work 
from single institutions have identified urinary biomarkers that may hold promise for the early 
detection of pancreatic cancer and predict risk (8-10).  Due to commercial availability of 
ELISAs, we selected TIMP-1, LYVE-1, and PGEM for testing in the present study to determine 
whether they may also have utility for predicting hi h-risk IPMN.  
We demonstrate that urinary TIMP-1 and LYVE-1 levels are significantly lower in 
healthy controls compared to PDAC, thus validating heir performance as previously reported (9, 
10).  However, urinary TIMP-1 and LYVE-1 levels did not correlate with IPMN dysplastic 
grade; this result was recently confirmed in our labor tory by quantitative proteomics showing 
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no difference in urinary TIMP-1 or LYVE-1 abundance between low/moderate-grade and high-
grade/invasive IPMN (unpublished results).  In their study of urinary LYVE-1 in PDAC, Radon 
et al showed that LYVE-1 levels tended to be higher in early stage PDAC than in IPMN (n=33), 
but the IPMNs were not classified by dysplastic grade (9).    
Similarly, urinary PGEM levels were not significantly different in any of the pancreatic 
lesions groups tested, from benign to invasive.  Wewere particularly interested in the 
performance of urinary PGEM since we had previously shown that in pancreatic cyst fluid, 
PGE2 levels may be predictive of IPMN malignant risk (11).  Other prior work from our 
laboratory has implicated the inflammatory pathway, including cyclooxygenase-2 and PGE2, in 
the development of pancreatic cancer (12).  Taken together, results from the present study 
suggest that although urinary TIMP-1 and LYVE-1 candifferentiate healthy from pancreatic 
cancer, none of the three markers tested can distinguish more subtle changes occurring during 
stages of IPMN malignant transformation.   
Limitations of the present study include the relatively small sample size and the testing of 
samples collected only from patients undergoing pancreatic resection.  In addition, the age of the 
healthy control group was significantly younger compared to the patient groups, although this 
was adjusted for in the statistical analysis.  Future studies should include prospective collection 
of additional samples, surgical as well as longitudinal during patient surveillance.  Longitudinal 
(serial samples from same patient prior to resection) instead of cross-sectional (one sample at 
time of resection) analysis of biomarker performance may provide more insight into biomarkers 
that correlate with disease progression over time. 
In conclusion, although it is reasonable to investigate markers that perform well in 
predicting pancreatic cancer, it may be unreasonable to expect the same biomarker to 
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discriminate between low- and high-risk IPMN.  Further complicating this pursuit, is the 
potential for inter-observer variability in characterizing dysplastic grades among pathologists.  
Nevertheless, the search must continue not only by testing the performance of existing 
biomarkers but also by identifying novel urinary biomarkers that can be included in a diagnostic 
panel.  Importantly, such biomarkers would complement the existing algorithm guiding the 
management of IPMN. 
REFERENCES  
1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: 
the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 
2014 Jun 1;74(11):2913-21. 
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 
Jan;69(1):7-34. 
3. Tanaka M. Intraductal Papillary Mucinous Neoplasm as the Focus for Early Detection of 
Pancreatic Cancer. Gastroenterology. 2018 Feb;154(3):475-8. 
4. Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al. 851 resected cystic tumors of the 
pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012 Sep;152(3 
Suppl 1):S4-12. 
5. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 
2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012 May-
Jun;12(3):183-97. 
6. Maker AV, Carrara S, Jamieson NB, et al. Cyst fluid biomarkers for intraductal papillary 
mucinous neoplasms of the pancreas: a critical review from the international expert meeting on 
10 
 
pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg. 2015 
Feb;220(2):243-53. 
7. Moris D, Damaskos C, Spartalis E, et al. Updates nd Critical Evaluation on Novel 
Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the 
Pancreas. Anticancer Res. 2017 May;37(5):2185-94. 
8. Cui Y, Shu XO, Li HL, et al. Prospective study of urinary prostaglandin E2 metabolite 
and pancreatic cancer risk. Int J Cancer. 2017 Dec 15;141(12):2423-9. 
9. Radon TP, Massat NJ, Jones R, et al. Identification of a Three-Biomarker Panel in Urine 
for Early Detection of Pancreatic Adenocarcinoma. Clin ancer Res. 2015 Aug 1;21(15):3512-
21. 
10. Roy R, Zurakowski D, Wischhusen J, et al. Urinary TIMP-1 and MMP-2 levels detect the 
presence of pancreatic malignancies. British journal of cancer. 2014 Oct 28;111(9):1772-9. 
11. Yip-Schneider MT, Carr RA, Wu H, Schmidt CM. Prostaglandin E2: A Pancreatic Fluid 
Biomarker of Intraductal Papillary Mucinous Neoplasm Dysplasia. J Am Coll Surg. 2017 
Oct;225(4):481-7. 
12. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in 
human pancreatic adenocarcinomas. Carcinogenesis. 2000;21(2):139-46. 
FIGURE LEGENDS 
Figure 1.  Urinary TIMP-1 and LYVE-1  
A) Normalized urinary TIMP-1 levels in healthy, low/moderate-grade IPMN, high-
grade/invasive IPMN and PDAC are shown in the scatter plot (horizontal lines - median, 
interquartile range).  B) Normalized urinary LYVE-1 levels in healthy, chronic pancreatitis (CP), 
low/moderate-grade IPMN, high-grade/invasive IPMN and PDAC groups are shown in the 
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scatter plot.  Statistically significant differences between groups are indicated; no significant 
differences were detected between low/moderate and high/invasive grades of IPMN. 
Figure 2. Urinary PGEM  
Normalized urinary PGEM levels were determined in pseudocyst, SCN, MCN, low/moderate-
grade IPMN, high-grade/invasive IPMN and PDAC (horiz ntal lines - median, interquartile 





IPMN (intraductal papillary mucinous neoplasm); PDAC (pancreatic ductal adenocarcinoma); 
TIMP-1 (Tissue Inhibitor of Metalloproteinase-1); LYVE-1 (Lymphatic Vessel Endothelial 
Receptor 1); PGEM (Prostaglandin E Metabolite); SCN (serous cystic neoplasm); MCN 
(mucinous cystic neoplasm) 
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Summary Sentences: 
Although urinary TIMP-1 and LYVE-1 can distinguish between healthy controls and PDAC, 
these two biomarkers are not able to differentiate between dysplastic grades of a precursor lesion 
known as IPMN.  Similarly, urinary PGEM levels do nt correlate with the malignant potential 










































































































































• Urinary TIMP-1 and LYVE-1 can differentiate healthy controls from pancreatic cancer 
• Urinary TIMP-1 and LYVE-1 cannot distinguish between low- and high-risk IPMN 
• Urinary PGEM does not correlate with malignant potential of pancreatic cysts 
 
